Literature DB >> 11054067

Cytogenetic and molecular diagnosis of chromosome 5 deletions in myelodysplasia.

C A Westbrook1, W T Hsu, B Chyna, D Litvak, A Raza, S K Horrigan.   

Abstract

Deletions of chromosome 5, del(5q), are frequently observed in myelodysplasia (MDS). We evaluated molecular detection of loss of heterozygosity (LOH) as a diagnostic method to detect del(5q) in a series of 60 MDS cases at a single institution. LOH was compared to cytogenetics on the same clinical specimen, resolving ambiguous cases by fluorescent in situ hybridization (FISH) and additional LOH. There was poor concordance between molecular and cytogenetic results, but most discrepancies could be resolved by FISH and additional LOH. Molecular analysis was of low sensitivity because most cases contained a relatively high proportion of cells without del(5q), but it was accurate, while cytogenetics overestimated the proportion of cells with del(5q) and failed to detect some cases with complex rearrangements. Minor clones were detected both by FISH and LOH. Overall, we found an incidence of 23% (14 of 60 cases) for del(5q) in MDS. The results also suggest that there is a high degree of genetic heterogeneity in the cellular population of MDS. Although del(5q) is common in MDS, it may not be present in all cells, leading to diagnostic challenges.

Entities:  

Mesh:

Year:  2000        PMID: 11054067     DOI: 10.1046/j.1365-2141.2000.02285.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype.

Authors:  Emanuele Ammatuna; Paola Panetta; Xabier Agirre; Tiziana Ottone; Serena Lavorgna; Maria José Calasanz; Francesco Lo-Coco
Journal:  Haematologica       Date:  2011-03-10       Impact factor: 9.941

2.  An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer.

Authors:  Piia-Riitta Karhemo; Antti Rivinoja; Johan Lundin; Maija Hyvönen; Anastasiya Chernenko; Johanna Lammi; Harri Sihto; Mikael Lundin; Päivi Heikkilä; Heikki Joensuu; Petri Bono; Pirjo Laakkonen
Journal:  Am J Pathol       Date:  2011-06-02       Impact factor: 4.307

3.  An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.

Authors:  Benjamin L Ebert; Naomi Galili; Pablo Tamayo; Jocelyn Bosco; Raymond Mak; Jennifer Pretz; Shyam Tanguturi; Christine Ladd-Acosta; Richard Stone; Todd R Golub; Azra Raza
Journal:  PLoS Med       Date:  2008-02       Impact factor: 11.069

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.